Crizotinib in patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer versus chemotherapy as a first-line treatment

類似資料

• Poor response to gefitinib in lung adenocarcinoma with concomitant epidermal growth factor receptor mutation and anaplastic lymphoma kinase rearrangement
  著者:: Zhou, Jianya, 等
  出版事項: (2015)
• Outcomes of switching from crizotinib to alectinib in patients with advanced non-small cell lung cancer with anaplastic lymphoma kinase fusion
  著者:: Pan, Yingying, 等
  出版事項: (2021)
• Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma
  著者:: Zhang, Quan, 等
  出版事項: (2015)
• Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma
  著者:: Xu, Wendan, 等
  出版事項: (2018)
• Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report
  著者:: Kothari, Shalin, 等
  出版事項: (2016)